Tysabri and PML: Key Facts for Washington Patients

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

Legacy of General Health and Science Information

If you or a loved one is taking Tysabri, understanding the risk of progressive multifocal leukoencephalopathy (PML) is critical for informed decision-making. The historical context of drug safety monitoring has shaped how we evaluate adverse events like PML. This guide covers PML symptoms, risk factors, and how to obtain your medical records in Washington.

Clinical Presentation and Diagnosis of PML

PML is an opportunistic viral infection of the brain that typically occurs only in immunocompromised individuals and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The condition results from reactivation of the JC virus, which damages oligodendrocytes and causes progressive demyelination. Clinical symptoms vary depending on the affected brain regions but commonly include cognitive decline, motor weakness, visual disturbances, and speech difficulties. Diagnosis is confirmed through brain MRI showing characteristic white matter lesions and detection of JCV DNA in cerebrospinal fluid via polymerase chain reaction. Early recognition is essential because the disease can progress rapidly. For patients in Washington who have developed PML after Tysabri exposure, understanding the medical evidence and legal considerations—including the statute of limitations for filing a claim—is critical.

Tysabri Pharmacology and PML Risk Factors

Tysabri is a monoclonal antibody that binds to alpha-4 integrins on leukocytes, preventing their migration across the blood-brain barrier. This mechanism reduces inflammatory activity in the central nervous system but also impairs immune surveillance, creating an environment permissive for JCV reactivation. The FDA-approved labeling identifies three primary risk factors for PML in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing therapy, and the expected benefit must be weighed against the PML risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Mechanistic Pathways Linking Tysabri to PML

The mechanistic link between Tysabri and PML centers on reduced immune surveillance in the brain. By blocking leukocyte trafficking, Tysabri diminishes the ability of the immune system to control latent JCV infection. The virus can then replicate unchecked, leading to lytic infection of oligodendrocytes and subsequent demyelination. This pathway is supported by the observation that PML risk increases with longer treatment duration and in patients with prior immunosuppressant use, both of which further compromise immune function.

Adequacy of Warnings and Settlement Considerations

Tysabri carries a boxed warning stating that it increases the risk of PML, an opportunistic viral infection that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The warning specifies that healthcare professionals should monitor patients for any new sign or symptom suggestive of PML and withhold Tysabri immediately at the first such indication. Additionally, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program, which requires patients to read a Medication Guide, understand the risks, and sign an enrollment form (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, questions may arise about whether the warnings were sufficiently clear or timely communicated to patients and prescribers, particularly regarding the cumulative nature of risk over time. For patients in Washington who have developed PML after Tysabri use, settlement considerations involve evaluating the timeline between exposure and documented harm. The statute of limitations for filing a personal injury lawsuit in Washington is generally three years from the date the injury was discovered or should have been discovered. Given that PML symptoms may develop insidiously and diagnosis can be delayed, the discovery date is a critical factor. Patients should consult with legal counsel to determine whether their claim falls within the applicable time frame. Settlement negotiations may also consider the severity of disability, medical expenses, lost income, and the adequacy of risk communication by the manufacturer.

Timeline Between Exposure and Documented Harm

The latency period between starting Tysabri and PML onset varies. The labeling notes that risk increases with longer treatment duration, especially beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, cases have been reported after shorter exposure. Once symptoms appear, the disease can progress rapidly, underscoring the importance of immediate discontinuation of Tysabri upon suspicion of PML. Documenting the exact timeline of treatment, symptom onset, and diagnosis is essential for both medical management and legal purposes.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Washington?

In Washington State, the statute of limitations for filing a personal injury lawsuit is generally three years from the date the injury was discovered or should have been discovered. For PML, which may develop insidiously, the discovery date is critical. Patients should consult with legal counsel to determine if their claim is timely.

What are the primary risk factors for PML in Tysabri patients?

The FDA-approved labeling identifies three primary risk factors: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Tysabri Prescribing Information (DailyMed)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.